WO2010133806A3 - Peptides marques et leur utilisation pour le dosage d'irap circulant - Google Patents

Peptides marques et leur utilisation pour le dosage d'irap circulant Download PDF

Info

Publication number
WO2010133806A3
WO2010133806A3 PCT/FR2010/050967 FR2010050967W WO2010133806A3 WO 2010133806 A3 WO2010133806 A3 WO 2010133806A3 FR 2010050967 W FR2010050967 W FR 2010050967W WO 2010133806 A3 WO2010133806 A3 WO 2010133806A3
Authority
WO
WIPO (PCT)
Prior art keywords
irap
assaying
marked
extracellular portion
marked peptides
Prior art date
Application number
PCT/FR2010/050967
Other languages
English (en)
Other versions
WO2010133806A2 (fr
Inventor
Serge Bottari
Georges Vauquelin
Dirk Tourwe
Original Assignee
Universite Joseph Fourier
Vrije Universiteit Brussel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Joseph Fourier, Vrije Universiteit Brussel filed Critical Universite Joseph Fourier
Priority to JP2012511327A priority Critical patent/JP2012527437A/ja
Priority to CA2762525A priority patent/CA2762525A1/fr
Priority to EP10728786A priority patent/EP2432800A2/fr
Priority to US13/321,576 priority patent/US20120115163A1/en
Publication of WO2010133806A2 publication Critical patent/WO2010133806A2/fr
Publication of WO2010133806A3 publication Critical patent/WO2010133806A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention a pour objet une méthode de dosage de la partie extracellulaire circulante de la protéine IRAP (« insulin responsive aminopeptidase ») comprenant au moins une étape de dosage quantitatif de ladite partie extracellulaire, sécrétée, purifiée, d'IRAP, au moyen d'au moins un peptide marqué, ledit peptide marqué interagissant spécifiquement avec ladite partie extracellulaire d'IRAP.
PCT/FR2010/050967 2009-05-20 2010-05-19 Peptides marques et leur utilisation pour le dosage d'irap circulant WO2010133806A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2012511327A JP2012527437A (ja) 2009-05-20 2010-05-19 標識ペプチド及び循環性ｉｒａｐのアッセイのためのその使用
CA2762525A CA2762525A1 (fr) 2009-05-20 2010-05-19 Peptides marques et leur utilisation pour le dosage d'irap circulant
EP10728786A EP2432800A2 (fr) 2009-05-20 2010-05-19 Peptides marques et leur utilisation pour le dosage d'irap circulant
US13/321,576 US20120115163A1 (en) 2009-05-20 2010-05-19 Marked peptides and use thereof for assaying circulating irap

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0953392A FR2945808B1 (fr) 2009-05-20 2009-05-20 Peptides marques et leur utilisation pour le dosage d'irap circulant
FR09/53392 2009-05-20

Publications (2)

Publication Number Publication Date
WO2010133806A2 WO2010133806A2 (fr) 2010-11-25
WO2010133806A3 true WO2010133806A3 (fr) 2011-03-03

Family

ID=41647165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2010/050967 WO2010133806A2 (fr) 2009-05-20 2010-05-19 Peptides marques et leur utilisation pour le dosage d'irap circulant

Country Status (6)

Country Link
US (1) US20120115163A1 (fr)
EP (1) EP2432800A2 (fr)
JP (1) JP2012527437A (fr)
CA (1) CA2762525A1 (fr)
FR (1) FR2945808B1 (fr)
WO (1) WO2010133806A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016140063A1 (fr) * 2015-03-04 2016-09-09 栄研化学株式会社 Procédé de mesure d'ocytocine de sensibilité élevée
CN115212322B (zh) * 2022-06-01 2024-01-16 原子高科股份有限公司 一种用于放射性药物制备的冻干药盒及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007047796A2 (fr) * 2005-10-17 2007-04-26 Institute For Systems Biology Glycoproteines derivees de tissus et du serum et leurs methodes d'utilisation
WO2007140906A1 (fr) * 2006-06-07 2007-12-13 Bayer Healthcare Ag Utilisation de la leucyl/cystinyl aminopeptidase (lnpep) en tant que cible thérapeutique ou diagnostique
US7473531B1 (en) * 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753875A (en) * 1981-11-02 1988-06-28 Ryan James W Method for assaying proteases with tagged proteinaceous inhibitors
WO2005038462A1 (fr) 2003-10-21 2005-04-28 Suntory Limited Methode d'evaluation pronostique du carcinome mettant en oeuvre un anticorps anti-lap-p

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473531B1 (en) * 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof
WO2007047796A2 (fr) * 2005-10-17 2007-04-26 Institute For Systems Biology Glycoproteines derivees de tissus et du serum et leurs methodes d'utilisation
WO2007140906A1 (fr) * 2006-06-07 2007-12-13 Bayer Healthcare Ag Utilisation de la leucyl/cystinyl aminopeptidase (lnpep) en tant que cible thérapeutique ou diagnostique

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ALBISTON ET AL: "Therapeutic targeting of insulin-regulated aminopeptidase: Heads and tails?", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB LNKD- DOI:10.1016/J.PHARMTHERA.2007.07.006, vol. 116, no. 3, 20 November 2007 (2007-11-20), pages 417 - 427, XP022354101, ISSN: 0163-7258 *
BERNIER SYLVIE G ET AL: "Characterization of AT4 receptor from bovine aortic endothelium with photosensitive analogues of angiotensin IV", BIOCHEMISTRY, vol. 37, no. 12, 24 March 1998 (1998-03-24), pages 4280 - 4287, XP002611372, ISSN: 0006-2960 *
DEMAEGDT H ET AL: "Selective labeling of IRAP by the tritiated AT4 receptor ligand [<3>H]Angiotensin IV and its stable analog [<3>H]AL-11", MOLECULAR AND CELLULAR ENDOCRINOLOGY, ELSEVIER IRELAND LTD, IE, vol. 311, no. 1-2, 13 November 2009 (2009-11-13), pages 77 - 86, XP026558305, ISSN: 0303-7207, [retrieved on 20090728], DOI: DOI:10.1016/J.MCE.2009.07.020 *
LEW REBECCA A ET AL: "Angiotensin AT4 ligands are potent, competitive inhibitors of insulin regulated aminopeptidase (IRAP).", JOURNAL OF NEUROCHEMISTRY, vol. 86, no. 2, July 2003 (2003-07-01), pages 344 - 350, XP002611371, ISSN: 0022-3042 *
LUKASZUK ANETA ET AL: "beta-homo-amino acid scan of angiotensin IV", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, no. 7, April 2008 (2008-04-01), pages 2291 - 2296, XP002568373, ISSN: 0022-2623 *
LUKASZUK ANETA ET AL: "The Replacement of His(4) in Angiotensin IV by Conformationally Constrained Residues Provides Highly Potent and Selective Analogues", JOURNAL OF MEDICINAL CHEMISTRY, vol. 52, no. 18, September 2009 (2009-09-01), pages 5612 - 5618, XP002611369, ISSN: 0022-2623 *
NARUKI M ET AL: "Oxytocin is hydrolyzed by an enzyme in human placenta that is identical to the oxytocinase of pregnancy serum", PEPTIDES (TARRYTOWN), vol. 17, no. 2, 1996, pages 257 - 261, XP002568374, ISSN: 0196-9781 *
TSUJIMOTO M ET AL: "Identification of human placental leucine aminopeptidase as oxytocinase", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, ACADEMIC PRESS, US, vol. 292, no. 2, 1 February 1992 (1992-02-01), pages 388 - 392, XP024759388, ISSN: 0003-9861, [retrieved on 19920201] *
TSUJIMOTO M ET AL: "The oxytocinase subfamily of M1 aminopeptidases", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - PROTEINS & PROTEOMICS, ELSEVIER LNKD- DOI:10.1016/J.BBAPAP.2004.09.011, vol. 1751, no. 1, 1 August 2005 (2005-08-01), pages 9 - 18, XP004995172, ISSN: 1570-9639 *
ZHANG JIAN-HUA ET AL: "Structural analysis of angiotensin IV receptor (AT4) from selected bovine tissues", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 289, no. 2, May 1999 (1999-05-01), pages 1075 - 1083, XP002611370, ISSN: 0022-3565 *

Also Published As

Publication number Publication date
FR2945808B1 (fr) 2013-12-27
JP2012527437A (ja) 2012-11-08
EP2432800A2 (fr) 2012-03-28
CA2762525A1 (fr) 2010-11-25
FR2945808A1 (fr) 2010-11-26
US20120115163A1 (en) 2012-05-10
WO2010133806A2 (fr) 2010-11-25

Similar Documents

Publication Publication Date Title
FR17C1020I2 (fr) Fsh recombinante comprenant la sialylation alpha 2,3 et alpha 2,6
BRPI0911780A8 (pt) compostos peguilados de hormônio de crescimento humano recombinante
ES2322882B1 (es) Peptidos inhibidores de la exocitosis neuronal.
BR112012004546A2 (pt) &#34;terapêutica por proteínas ligantes dll4-ligantes&#34;
HK1155330A1 (en) Oilseed protein concentrates and isolates, and processes for the production thereof
BRPI0815368A2 (pt) &#34;proteinas c-fms humanas a antigeno&#34;
WO2011044089A3 (fr) Procédés de traitement de la dépression et d&#39;autres maladies associées
PL1865976T3 (pl) Zastosowanie peptydu natriuretycznego do leczenia niewydolności serca
DK2035447T3 (da) Polypeptid
IL184284A0 (en) Modified beta thymosin peptides
DK2001518T3 (da) Cykliske natriuretiske peptidfremstillinger
WO2008093058A3 (fr) Peptides et leur utilisation
IL223076A0 (en) Novel as160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics
HK1171048A1 (zh) 重組人干擾素樣蛋白
WO2006042745A3 (fr) Analogues de peptides modifies chimiquement
WO2009064366A3 (fr) Procédés et compositions pour un marquage protéique à l&#39;aide d&#39;acide lipoïque ligases
WO2009047513A3 (fr) Composé, utilisation et procédé
WO2011123858A3 (fr) Peptides ccn3 à visée thérapeutique et leurs analogues
DK2207790T3 (da) Biologisk aktive C-terminalt argininholdige peptider
EP2281003A4 (fr) Anticorps humanisés spécifiques pour une séquence d&#39;acides aminés rgd d&#39;une protéine matricielle extracellulaire et leurs utilisations
EP2371840A4 (fr) Nouveau polypeptide avec activités d&#39;induction d&#39;angiogenèse et antibactérienne, et son utilisation à des fins médicales
EP2102231A4 (fr) Système d&#39;expression améliorée pour l&#39;arginase i humaine recombinante
WO2010133806A3 (fr) Peptides marques et leur utilisation pour le dosage d&#39;irap circulant
EP1999261A4 (fr) Utilisation de la fusion de la proteine s permettant une solubilisation proteique
EP2480665A4 (fr) Anticorps humanisés spécifiques d&#39;une séquence rgd d&#39;acides aminés d&#39;une protéine matricielle extracellulaire et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10728786

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2762525

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012511327

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2010728786

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010728786

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13321576

Country of ref document: US